KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $2.7 billion.

  • Alnylam Pharmaceuticals' Cash & Current Investments fell 170.6% to $2.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 billion, marking a year-over-year decrease of 170.6%. This contributed to the annual value of $2.7 billion for FY2024, which is 1053.11% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Cash & Current Investments of $2.7 billion as of Q3 2025, which was down 170.6% from $2.9 billion recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Cash & Current Investments peaked at $2.9 billion during Q2 2025, and registered a low of $1.7 billion during Q1 2021.
  • Its 5-year average for Cash & Current Investments is $2.3 billion, with a median of $2.4 billion in 2024.
  • The largest annual percentage gain for Alnylam Pharmaceuticals' Cash & Current Investments in the last 5 years was 3358.38% (2022), contrasted with its biggest fall of 870.97% (2022).
  • Over the past 5 years, Alnylam Pharmaceuticals' Cash & Current Investments (Quarter) stood at $2.4 billion in 2021, then decreased by 8.71% to $2.2 billion in 2022, then increased by 12.3% to $2.4 billion in 2023, then increased by 10.53% to $2.7 billion in 2024, then rose by 1.42% to $2.7 billion in 2025.
  • Its Cash & Current Investments was $2.7 billion in Q3 2025, compared to $2.9 billion in Q2 2025 and $2.6 billion in Q1 2025.